Figure 6

The expression of AMPK in muscle tissue was decreased in COPD model rats, and AICAR or resveratrol treatment recovered AMPK expression in COPD model rats. (A) Sample blots of AMPK and β-actin. Normalized muscle AMPK mRNA (B; Control: n = 14; COPD/saline: n = 12, 0.35 ± 0.04; COPD/AICAR, n = 14, 1.50 ± 0.12; COPD/Resveratrol, n = 12, 0.96 ± 0.05; ***F _{1, 25} = 68.31, p < 0.001 comparing the control group to the COPD/saline group; **F _{1, 27} = 11.89, p = 0.002 comparing the control group to the COPD/AICAR group; ###F _{1, 23} = 74.98, p < 0.001 comparing COPD/saline to COPD/resveratrol; ###F _{1, 25} = 60.98, p < 0.001 comparing COPD/saline to COPD/AICAR group). Normalized muscle AMPK protein (C; Control: n = 14; COPD/saline: n = 12, 0.32 ± 0.03; COPD/AICAR, n = 14, 0.96 ± 0.04; COPD/resveratrol, n = 12, 0.66 ± 0.01; ***F _{1, 25} = 66.17, p < 0.001 comparing the control group to the COPD/saline group; ***F _{1, 25} = 25.21, p < 0.001 comparing the control group to the COPD/resveratrol group; n.s. F _{1, 27} = 0.16, p = 0.70 comparing the control group to the COPD/AICAR; ###F _{1, 25} = 31.52, p < 0.001 comparing COPD/saline to COPD/AICAR; ###F _{1, 23} = 24.58, p < 0.001 comparing COPD/saline to COPD/resveratrol group. n.s. (not significant). Normalized muscle p-AMPK protein (D; Control: n = 6; COPD/saline: n = 6, 0.58 ± 0.14; COPD/AICAR, n = 6, 1.26 ± 0.30; COPD/resveratrol, n = 6, 1.29 ± 0.30; * F _{1, 11} = 5.1, p < 0.05 comparing the control group to the COPD/saline group; ###F _{2, 17} = 15.15, p < 0.001 comparing COPD/saline to COPD/AICAR and COPD/resveratrol. n.s. F _{2, 17} = 0.093 comparing the control group to the COPD/resveratrol group and COPD/resveratrol. n.s. (not significant).